Keywords: Takeda, Alogliptin, Actos, USA, FDA, CRL, Type 2 diabetes

US FDA again delays action on Takeda's alogliptin diabetes drug

Article | 26 April 2012

Print This

Japan’s largest drugmaker Takeda Pharmaceutical (TYO: 4502) says it has received a complete response letter from the US Food ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in